Bioinformatics analysis shows SNHG25 promotes tumor progression and is linked to immune infiltration in colon adenocarcinoma, suggesting new therapeutic drugs.
Key Points
SNHG25 is highly expressed in colon adenocarcinoma samples, and its diagnostic ability is strong with an AUC of 0.937.
Functional enrichment analysis reveals that high SNHG25 expression activates oxidative phosphorylation pathways, compared to low expression tied to immune signaling.
Observational analysis of immune infiltration indicates SNHG25 correlates with various immune cell types, influencing the tumor immune microenvironment.
Three therapeutic drugs, including demecolcine and vorinostat, were predicted based on SNHG25, which is validated by molecular docking results.